Advertisement
UK markets closed
  • FTSE 100

    8,275.38
    +44.33 (+0.54%)
     
  • FTSE 250

    20,730.12
    +59.25 (+0.29%)
     
  • AIM

    805.79
    +3.10 (+0.39%)
     
  • GBP/EUR

    1.1736
    -0.0013 (-0.11%)
     
  • GBP/USD

    1.2731
    -0.0001 (-0.01%)
     
  • Bitcoin GBP

    52,851.77
    -1,539.55 (-2.83%)
     
  • CMC Crypto 200

    1,415.79
    -12.78 (-0.90%)
     
  • S&P 500

    5,213.97
    -21.51 (-0.41%)
     
  • DOW

    38,297.17
    +185.69 (+0.49%)
     
  • CRUDE OIL

    77.21
    -0.70 (-0.90%)
     
  • GOLD FUTURES

    2,345.00
    -21.50 (-0.91%)
     
  • NIKKEI 225

    38,487.90
    +433.80 (+1.14%)
     
  • HANG SENG

    18,079.61
    -150.59 (-0.83%)
     
  • DAX

    18,497.94
    +1.15 (+0.01%)
     
  • CAC 40

    7,992.87
    +14.36 (+0.18%)
     

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Conference Call & Webcast

Thursday, May 9th @ 4:30 PM ET

Domestic:

1-888-886-7786

International:

1-416-764-8658

Conference ID:

71864759

 

 

Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.

ADVERTISEMENT

Call me™: https://emportal.ink/3xjDV8X

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1664624&tp_key=4756f5f4c0

About Crinetics Pharmaceuticals 
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, first-in-class, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.

Contact:
Corey Davis
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
(212) 915-2577

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
858 345-6075

Source: Crinetics Pharmaceuticals, Inc.